<DOC>
	<DOCNO>NCT00121381</DOCNO>
	<brief_summary>Atopic dermatitis , also call eczema , characterize redness , papulation ( skin elevation ) pruritus ( skin itching ) . The active ingredient pimecrolimus inhibit T-cell activation . These cell involve inflammatory component disease . This study test safety pimecrolimus Cream 1 % topical corticosteroid treatment ( commonly use eczema ) patient severe atopic dermatitis .</brief_summary>
	<brief_title>Pimecrolimus Cream 1 % Plus Topical Corticosteroid Patients ( 2-17 Years Age ) With Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Severe atopic dermatitis 5 % total body surface area ( TBSA ) affect Concurrent skin disease ( infection ) Immunocompromised Recently receive phototherapy systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>T-cell</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>child</keyword>
	<keyword>topical corticosteroid</keyword>
</DOC>